Zacks: Analysts Anticipate Evolent Health Inc (EVH) Will Post Quarterly Sales of $141.88 Million

Analysts expect Evolent Health Inc (NYSE:EVH) to report sales of $141.88 million for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Evolent Health’s earnings. The highest sales estimate is $142.75 million and the lowest is $140.70 million. Evolent Health posted sales of $107.32 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 32.2%. The business is scheduled to report its next quarterly earnings results on Monday, August 6th.

On average, analysts expect that Evolent Health will report full year sales of $578.14 million for the current year, with estimates ranging from $574.40 million to $585.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $668.67 million per share, with estimates ranging from $653.96 million to $680.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Evolent Health.

Get Evolent Health alerts:

Evolent Health (NYSE:EVH) last announced its earnings results on Wednesday, May 9th. The technology company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.06. Evolent Health had a negative return on equity of 2.16% and a negative net margin of 12.11%. The company had revenue of $139.70 million for the quarter, compared to analyst estimates of $140.89 million. During the same period in the prior year, the company posted ($0.14) EPS. Evolent Health’s quarterly revenue was up 31.5% on a year-over-year basis.

A number of brokerages have issued reports on EVH. MED upped their target price on Evolent Health from $22.00 to $31.00 and gave the company an “outperform” rating in a research report on Monday, June 18th. SunTrust Banks upped their target price on Evolent Health and gave the company a “buy” rating in a research report on Thursday, June 7th. KeyCorp upped their target price on Evolent Health from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, June 7th. TheStreet raised Evolent Health from a “d+” rating to a “c-” rating in a research report on Monday, June 4th. Finally, Piper Jaffray Companies started coverage on Evolent Health in a research report on Monday, June 4th. They set an “overweight” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $26.08.

In related news, President Seth Blackley sold 85,596 shares of the firm’s stock in a transaction dated Tuesday, May 8th. The stock was sold at an average price of $17.08, for a total transaction of $1,461,979.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Frank J. Williams sold 15,000 shares of the company’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $20.04, for a total value of $300,600.00. The disclosure for this sale can be found here. Insiders have sold 3,102,665 shares of company stock valued at $59,506,082 in the last ninety days. Company insiders own 4.82% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Paloma Partners Management Co lifted its holdings in shares of Evolent Health by 92.8% during the fourth quarter. Paloma Partners Management Co now owns 32,768 shares of the technology company’s stock valued at $403,000 after purchasing an additional 15,769 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Evolent Health by 30.5% during the fourth quarter. US Bancorp DE now owns 28,263 shares of the technology company’s stock valued at $348,000 after purchasing an additional 6,609 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Evolent Health by 124.0% during the fourth quarter. Bank of Montreal Can now owns 23,917 shares of the technology company’s stock valued at $294,000 after purchasing an additional 13,240 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Evolent Health during the fourth quarter valued at $172,000. Finally, Cortina Asset Management LLC lifted its holdings in shares of Evolent Health by 43.4% during the fourth quarter. Cortina Asset Management LLC now owns 413,406 shares of the technology company’s stock valued at $5,085,000 after purchasing an additional 125,053 shares during the last quarter.

Shares of Evolent Health traded up $0.35, reaching $23.15, during trading on Tuesday, according to MarketBeat. The company’s stock had a trading volume of 1,402,232 shares, compared to its average volume of 1,165,431. Evolent Health has a twelve month low of $10.30 and a twelve month high of $27.25. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -33.07 and a beta of 1.14. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.12.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Brokerages Set CTI BioPharma Corp (CTIC) Target Price at $7.10

Shares of CTI BioPharma Corp (NASDAQ:CTIC) have received an average recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.10.

Several analysts recently commented on CTIC shares. Cann reaffirmed a “buy” rating and set a $5.00 price objective on shares of CTI BioPharma in a research note on Wednesday, March 7th. Oppenheimer started coverage on CTI BioPharma in a research note on Friday, February 23rd. They set an “outperform” rating and a $5.00 price objective on the stock. BidaskClub downgraded CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 1st. Needham & Company LLC started coverage on CTI BioPharma in a research note on Monday, March 26th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Zacks Investment Research raised CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Wednesday, April 25th.

Get CTI BioPharma alerts:

CTI BioPharma traded up $0.18, hitting $5.08, during mid-day trading on Friday, MarketBeat.com reports. 5,420,700 shares of the company’s stock were exchanged, compared to its average volume of 386,918. The company has a market capitalization of $291.62 million, a PE ratio of -4.10 and a beta of 0.15. CTI BioPharma has a fifty-two week low of $2.45 and a fifty-two week high of $5.28. The company has a current ratio of 5.32, a quick ratio of 5.30 and a debt-to-equity ratio of 0.17.

CTI BioPharma (NASDAQ:CTIC) last issued its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. The business had revenue of $10.48 million for the quarter, compared to the consensus estimate of $10.30 million. CTI BioPharma had a negative return on equity of 63.27% and a negative net margin of 71.30%. analysts predict that CTI BioPharma will post -0.95 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in CTI BioPharma during the 1st quarter worth about $3,068,000. Element Capital Management LLC bought a new position in CTI BioPharma during the 1st quarter worth about $205,000. Barclays PLC increased its holdings in CTI BioPharma by 9,349.0% during the 1st quarter. Barclays PLC now owns 49,324 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 48,802 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in CTI BioPharma during the 1st quarter worth about $479,000. Finally, Franklin Resources Inc. bought a new position in CTI BioPharma during the 1st quarter worth about $13,542,000. Hedge funds and other institutional investors own 62.78% of the company’s stock.

CTI BioPharma Company Profile

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

The U.S. Education System Is Broken – and Companies Like This One Are Fixing It

Tim Melvin

I want to try a quick relaxation exercise.

This might sound crackpot, but just bear with me for a second.

Let's all take a deep breath, conservatives and liberals alike, and admit, out loud, the one thing that is true, regardless of where you land on the political spectrum.

Say it with me…

The U.S. education system is screwed up beyond what any of us would have thought was possible.

Looking at the results of the Program for International Student Assessment (PISA) tests, we score in the middle of most educational-achievement levels. We once had the best educational system in the world. Now, we're the Oakland Athletics of the global education system – a once-mighty enterprise now lucky to just be mediocre.

The problem has never been a lack of money…

The United States, on average, spends about 30% more per child than the average developed nation. Only Norway, Switzerland, and Austria spend more per kid that we do.

It just seems that the more we spend, the worse it gets. We've been trying to money-whip the education system into line for decades now, and if anything, we're only seeing an inverse relationship grow between money and results.

[URGENT] You could be owed $23,441 in drastically underpaid funds…

But the opposite is true of the education system's fastest-growing area – one that I've been watching like a hawk lately.

In fact, I just found one company in this particular area that's a strong "Buy" right now – and it's set to keep profiting from the fact that the U.S. public school system is, quite frankly, a giant mess…

Public Education Is a Joke, and Our Kids and Teachers Are the Punchline

For years, I helped broker a lot of municipal-bond deals, and that required digging through hundreds of school district bond-offering prospectuses.

Yes, these are often just as boring as they sound. But I highly recommend parsing through your local school board budget every now and then if you really want to get an idea of just how staggeringly wasteful our country's education system has become.

The amount of money poured in at the top and the amount that comes out the bottom in the actual classroom sums up the problem perfectly. Millions in cash are sucked out by an overweight and hyper-productive bureaucracy, and our kids pay the price.

Another part of the problem – and honestly, the most unbelievably infuriating – is the fact that we pay our teachers like serfs.

I saw how the public education system exploits teachers when my daughter was top of her class, won several awards while studying to be a teacher, and received high marks for her teacher-training systems. She worked her ass off for years, and the best offer she received as a first-year teacher was an annual salary less than $30,000.

At the same time, there were hundreds of administrators in the system making over $100,000 annually just to sit in their offices soaking up the benefits of a broken bureaucracy.

We can go on and on about the causes of the problem: the teachers unions' stranglehold on curriculum, standardized-testing issues, and a lack of parental participation, among many, many others. Each is more exasperating than the last.

You Must Act Now: America is headed for an economic disaster bigger than anything since the Great Depression. If you lost out when the markets crashed in 2008, then you are going to want to see this special presentation…

But the point I want to make is that I truly believe these are problems we can all agree on. My right-wing buddies can find as much to hate in the modern educational system as my liberal wingnut friends can.

Universally, our schools are letting our kids down, and more parents are making the decision to homeschool their kids.

Homeschooling has become the answer to the public education system's failings, and it's already showing up in the numbers. The National Center for Education Statistics reported the number of homeschooled kids in the United States grew from 850,000 to 1.8 million between 1999 and 2012. Since then, the number has easily surpassed 2 million.

Make no mistake: there's a lot of money to be made from homeschooling's growing popularity.

And those of us willing to sit toward the front of the classroom can position ourselves to make a killing from this trend.

It all starts with one company that sells a type of homeschooling education software used by nearly half of all high school students in the United States…

Here's How We'll Make Money from the Advent of Homeschooling

Join the conversation. Click here to jump to comments…

Tim Melvin

About the Author

Browse Tim's articles | View Tim's research services

The world's biggest advertiser wants women to produce half of its ads

The world's biggest advertiser is pushing for gender equality in the ad business.

Procter & Gamble, the consumer products conglomerate that makes Tide, Bounty, Old Spice, Pampers and Gillette, set a goal Monday to have women direct at least half its commercials by 2023. Women direct only 10% of commercials today.

P&G, which spends $7 billion a year on ads, also committed to pushing for gender equality in top marketing and creative jobs at advertising agencies. Women fill a little more than 30% of those positions today, according to an Association of National Advertisers study.

P&G doesn't make its own ads, but it's taking steps with ad agencies and partners to fulfill its commitment.

It's teaming with Queen Latifah and Katie Couric, who are both active in supporting female directors in television and movies through their media and entertainment companies. P&G will sponsor a new video project that Couric is leading.

The company is also signing the "Free the Bid" pledge, which aims to ensure that at least one woman is among the finalists to direct every commercial.

P&G hopes its commitment will encourage other companies to advance gender equality in advertising.

"We also know no company can do it alone, so we hope to inspire others to be agents of change to accelerate momentum," chief brand officer Marc Pritchard said in a news release.

P&G also believes it's good for business. Ads that promote gender equality lead to higher sales growth, the Association of National Advertisers study found.

"Some of P&G's best performing brands have the most gender-equal campaigns," Pritchard said. "It's clear that promoting gender equality is not only a force for good, it's a force for growth."

Pritchard pointed to Always' "Like a Girl" and Olay's "Live Fearlessly" ads as examples of gender-equal campaigns that have succeeded.